Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BACLOFEN vs ALBENZA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
Albendazole is a benzimidazole carbamate that inhibits tubulin polymerization by binding to the colchicine site of β-tubulin, disrupting microtubule formation. This leads to impaired uptake of glucose and depletion of glycogen stores, resulting in immobilization and death of susceptible helminths.
Spasticity due to multiple sclerosis (FDA approved),Spinal cord injury (FDA approved),Intrathecal use for severe spasticity of cerebral origin (off-label),Hiccups (off-label),Alcohol withdrawal syndrome (off-label),Trigeminal neuralgia (off-label)
FDA-approved: Hydatid disease (Echinococcus granulosus) and neurocysticercosis (Taenia solium).,Off-label: Ascariasis, trichuriasis, hookworm infections, enterobiasis, strongyloidiasis, cutaneous larva migrans, giardiasis, microsporidiosis, and other parasitic infestations.
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis.
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
Terminal elimination half-life of albendazole sulfoxide (active metabolite) is 8-12 hours; albendazole itself has a very short half-life (<1 hour) due to extensive first-pass metabolism.
Metabolized via hepatic deamination by transaminase; primarily excreted unchanged in urine (approximately 70-80%), with minor hepatic metabolism.
Primarily metabolized by hepatic microsomal enzymes, specifically to albendazole sulfoxide (active metabolite) via CYP3A4 and possibly other CYP isoforms. Further metabolized to albendazole sulfone (inactive) and other metabolites.
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
Primarily biliary/fecal (less than 2% renal as unchanged drug and metabolites; most eliminated via bile into feces as metabolites).
30-35% bound to albumin.
Albendazole: ~70% bound to plasma proteins (mainly albumin). Albendazole sulfoxide: ~70% bound.
Vd: 0.5-0.7 L/kg; indicates distribution into total body water.
Albendazole sulfoxide: 0.8-1.2 L/kg, indicating extensive tissue distribution including bile and CSF.
Oral: 70-85% with high variability; intrathecal: 100%.
Oral: Poor bioavailability (~5-10%) of parent drug due to extensive first-pass metabolism; enhanced (up to 5-fold) with high-fat meal. Not administered parenterally.
Cr Cl 30-50 m L/min: reduce dose by 50%; Cr Cl <30 m L/min: avoid use or use with extreme caution, reduce dose by 75%.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
No specific guidelines; use with caution due to potential for increased sedation/neurotoxicity.
Contraindicated in patients with known cirrhosis (Child-Pugh C). For mild to moderate hepatic impairment (Child-Pugh A or B), monitor liver function; dose adjustment not established.
Children 2-7 years: initial 2.5 mg orally 4 times daily, increase by 2.5 mg/dose every 3 days to max 40 mg/day; children ≥8 years: initial 5 mg orally 3 times daily, increase as in adults to max 60 mg/day.
For children ≥2 years: 400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis. For children <2 years: not recommended.
Start at low end of dosing range (5 mg twice daily), titrate slowly due to increased risk of sedation, weakness, and cognitive impairment.
No specific dose adjustment recommended; use with caution due to potential hepatic and renal decline. Monitor for adverse effects.
Abrupt discontinuation may cause withdrawal symptoms including hallucinations, seizures, and life-threatening hyperpyrexia; taper dose gradually.
NOT FDA APPROVED FOR ANY INDICATION IN THE UNITED STATES. (Note: This warning applies as Albendazole is not FDA-approved for use in the US; however, it is marketed elsewhere. In the US, it is available under an investigational protocol or as a compounded product.)
May cause CNS depression (drowsiness, sedation) and impair ability to drive or operate machinery.,Risk of withdrawal syndrome including fever, altered mental status, and autonomic instability upon abrupt cessation.,Use with caution in patients with renal impairment; dose adjustment required.,May exacerbate psychiatric disorders; monitor for hallucinations, confusion.,Risk of respiratory depression when combined with other CNS depressants.
Bone marrow suppression: Monitor blood counts regularly; risk of agranulocytosis, pancytopenia.,Hepatotoxicity: Elevation of liver enzymes; contraindicated in patients with hepatic disease or abnormal liver function tests.,Neurotoxicity: Risk of seizures, especially in neurocysticercosis due to inflammatory response to dying parasites.,Carcinogenicity: Long-term use associated with increased risk of tumors in animal studies.,Pregnancy: Category D (positive evidence of human fetal risk); avoid use in pregnant women or those likely to become pregnant.
Hypersensitivity to baclofen.,Intrathecal formulation is contraindicated in patients with active infection or bleeding disorders at lumbar puncture site.,Women who are breastfeeding (relative contraindication).
Hypersensitivity to albendazole or benzimidazole compounds.,Pregnancy (Category D) and lactation.,Pre-existing hepatic disease or unexplained liver function test abnormalities.,Bone marrow depression or severe neutropenia.
No specific food interactions. Avoid alcohol due to additive CNS depression.
Albendazole absorption is enhanced by fatty foods; a high-fat meal increases plasma concentration of the active metabolite albendazole sulfoxide by up to 5-fold. Avoid grapefruit juice as it may alter metabolism via CYP3A4 inhibition. Fatty meals are recommended to maximize efficacy.
First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third trimesters: Risk of neonatal withdrawal (hypertonia, seizures) with chronic maternal use. Avoid unless benefit outweighs risk.
Albendazole is contraindicated in pregnancy, especially during the first trimester. It has been shown to be embryotoxic and teratogenic in animals. In humans, there are reports of congenital malformations when used during pregnancy, including craniofacial defects and limb abnormalities. Use is not recommended in women who are or may become pregnant.
Baclofen excreted into breast milk in low concentrations (M/P ratio approximately 0.43). Relative infant dose estimated 0.9% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for sedation and hypotonia.
Albendazole is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 0.1. Due to potential adverse effects in nursing infants (e.g., bone marrow suppression, hepatic effects), caution is advised. The manufacturer recommends discontinuing breastfeeding or the drug, taking into account the importance of the drug to the mother.
No specific dose adjustments recommended. Increased renal blood flow and GFR in pregnancy may reduce baclofen levels; monitor clinical effect and adjust dose as needed. Avoid abrupt discontinuation due to risk of maternal withdrawal and rebound spasticity.
No specific dosing adjustments for pregnancy are established. Use is contraindicated in pregnancy due to teratogenicity. If treatment is necessary, avoid during first trimester and use the lowest effective dose for the shortest duration under strict medical supervision. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered metabolism) may require therapeutic drug monitoring if available.
Abrupt withdrawal can cause severe rebound spasticity, fever, and rhabdomyolysis; taper by 5-10 mg/week. Intrathecal baclofen pumps require careful monitoring for overdose (respiratory depression) or withdrawal. Use with caution in renal impairment (dose adjust for Cr Cl <30 m L/min).
Albendazole is a broad-spectrum anthelmintic effective against intestinal and tissue nematodes, cestodes, and some protozoa. It is poorly absorbed orally; co-administration with a fatty meal significantly increases bioavailability (up to 5-fold). Monitor liver function tests periodically due to risk of hepatotoxicity. Contraindicated in pregnancy (category C) and in patients with known hypersensitivity. For neurocysticercosis, concomitant corticosteroids and antiepileptics are often required to manage inflammatory reactions. May cause bone marrow suppression; obtain CBC at baseline and periodically. Dose adjustment not needed in renal impairment but caution in hepatic impairment.
Do not stop taking baclofen suddenly; sudden discontinuation can cause serious withdrawal symptoms including hallucinations, seizures, and high fever.,Avoid alcohol and CNS depressants as they increase sedation and risk of falls.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Take exactly as prescribed; missed doses can lead to muscle spasms or withdrawal.,Report any unusual muscle stiffness, rapid heart rate, or dark urine immediately.
Take with a high-fat meal to increase absorption.,Complete the full course of therapy even if symptoms improve.,Use effective contraception during treatment and for at least 1 month after the last dose.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, right upper quadrant pain.,May cause dizziness; avoid driving or operating machinery if affected.,Notify your healthcare provider if you experience persistent sore throat, fever, or unusual bleeding/bruising.
"Sevoflurane enhances the inhibitory effects of baclofen on the central nervous system by potentiating GABA-B receptor activity, leading to an increased risk of profound sedation, respiratory depression, and hypotension. This synergistic interaction can result in prolonged recovery from anesthesia and the need for ventilatory support. Clinically, patients may exhibit exaggerated muscle relaxation and a delayed emergence from anesthesia, particularly at higher doses of either agent."
"Concomitant use of etidocaine, an amide-type local anesthetic that blocks voltage-gated sodium channels, and baclofen, a GABAB receptor agonist used for muscle spasticity, may lead to additive central nervous system (CNS) depression and respiratory depression. This interaction results from synergistic depressant effects on the brainstem and spinal cord, increasing the risk of sedation, dizziness, ataxia, and impaired consciousness. Clinically, patients may experience excessive drowsiness, respiratory compromise, and impaired motor coordination, particularly in the elderly or those with pre-existing renal impairment where baclofen accumulation is more likely."
"The coadministration of Baclofen and Metaxalone results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic and sedative pathways. This combination can potentiate sedation, dizziness, ataxia, and respiratory depression, particularly in elderly patients or those with renal impairment. Clinical outcomes may include increased risk of falls, cognitive impairment, and impaired motor coordination, necessitating cautious dose titration."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BACLOFEN vs ALBENZA, answered by our medical review team.
BACLOFEN is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.. ALBENZA is a Anthelmintic that works by Albendazole is a benzimidazole carbamate that inhibits tubulin polymerization by binding to the colchicine site of β-tubulin, disrupting microtubule formation. This leads to impaired uptake of glucose and depletion of glycogen stores, resulting in immobilization and death of susceptible helminths.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BACLOFEN and ALBENZA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BACLOFEN is: Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.. The standard adult dose of ALBENZA is: 400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BACLOFEN and ALBENZA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BACLOFEN is classified as Category C. First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third t. ALBENZA is classified as Category C. Albendazole is contraindicated in pregnancy, especially during the first trimester. It has been shown to be embryotoxic and teratogenic in animals. In humans, there are reports of . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.